Coya Therapeutics (COYA) News Today → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free COYA Stock Alerts $9.92 +0.27 (+2.80%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Coya Therapeutics, Inc. (NASDAQ:COYA) Rises By 123.4%marketbeat.com - March 28 at 4:33 PMWe're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Ratefinance.yahoo.com - March 27 at 9:54 AMCritical Survey: Coya Therapeutics (COYA) versus The Competitionamericanbankingnews.com - March 27 at 6:18 AMComparing Coya Therapeutics (COYA) and Its Competitorsamericanbankingnews.com - March 26 at 1:22 AMCoya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updatesfinance.yahoo.com - March 21 at 10:20 AMCoya Therapeutics (NASDAQ:COYA) Price Target Raised to $14.00 at Chardan Capitalamericanbankingnews.com - March 21 at 4:30 AMCoya Therapeutics (NASDAQ:COYA) PT Raised to $14.00marketbeat.com - March 20 at 8:11 AMCOYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023investorplace.com - March 19 at 11:07 PMCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Resultsfinance.yahoo.com - March 19 at 8:28 AMCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Down 6.3% in Februarymarketbeat.com - March 18 at 10:55 AMCoya presents promising ALS biomarker data at conferenceinvesting.com - March 14 at 6:13 PMNew treatment for ALS provides hope for Maine families battling diseasemsn.com - March 13 at 1:59 AMCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conferencefinance.yahoo.com - March 12 at 10:16 AMCoya Therapeutics to Participate in BTIG Fireside Discussionfinance.yahoo.com - March 12 at 10:16 AMBuy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment Approachmarkets.businessinsider.com - March 10 at 10:38 PMBuy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel Optimismmarkets.businessinsider.com - March 8 at 7:31 AMCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conferencefinance.yahoo.com - February 29 at 9:24 AMAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)markets.businessinsider.com - February 22 at 12:44 PMCoya Inches up Ahead of ALS Addressmsn.com - February 22 at 12:44 PMCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conferencebusinesswire.com - February 22 at 8:15 AMCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"finance.yahoo.com - February 21 at 8:35 AMCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”businesswire.com - February 21 at 8:15 AMCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseasesfinance.yahoo.com - February 13 at 12:56 PMCoya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseasesbenzinga.com - February 5 at 2:57 PMBuy Rating Affirmed for Coya Therapeutics Amid Promising Drug Development and Regulatory Milestonesmarkets.businessinsider.com - February 1 at 9:18 AMCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conferencefinance.yahoo.com - January 29 at 10:08 AMCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Seriesfinance.yahoo.com - January 18 at 1:11 PMCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosisfinance.yahoo.com - January 16 at 12:35 PMDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financingfinance.yahoo.com - January 16 at 7:34 AMCoya Therapeutics Plans COYA 302 IND Application In Q2 - Quick Factsmarkets.businessinsider.com - January 5 at 9:28 AMCoya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)finance.yahoo.com - January 5 at 9:28 AMOptimistic Outlook on Dyne Therapeutics Backed by Promising Early Trial Resultsmarkets.businessinsider.com - January 4 at 7:10 PMCoya Therapeutics files to sell 4.69M shares for holdersmsn.com - January 4 at 7:10 PMCoya Therapeutics Stock (NASDAQ:COYA) Dividends: History, Yield and Datesbenzinga.com - December 21 at 8:06 PMMr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.finance.yahoo.com - December 20 at 10:35 AMDavid Einhorn's Greenlight Capital Boosts Coya Therapeutics Holdingfinance.yahoo.com - December 14 at 5:33 PMDavid Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfoliofinance.yahoo.com - December 14 at 5:33 PMStrong Buy Rating for Coya Therapeutics Amid Enhanced Financial Health and Strategic Partnershipsmarkets.businessinsider.com - December 14 at 7:32 AMCoya Therapeutics Announces Closing of $26.5 Million Private Placementfinance.yahoo.com - December 12 at 12:26 PMCoya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drugmarketwatch.com - December 6 at 10:12 PMDr Reddy's licenses Coya ALS candidate in exclusive dealmsn.com - December 6 at 10:12 PMCoya Therapeutics to Sell $26.5 Million of Stock in Private Placementmarketwatch.com - December 6 at 12:11 PMDr Reddy's inks pact with Coya Therapeutics for investigational ALS therapy COYA 302msn.com - December 6 at 12:11 PMCoya Therapeutics Sets Private Offering Of 4.370 Mln Shares At $6.06/shrmarkets.businessinsider.com - December 6 at 12:11 PMCoya Therapeutics Announces $26.5 Million Private Placementfinance.yahoo.com - December 6 at 12:11 PMCoya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)finance.yahoo.com - December 6 at 7:10 AMmarketbeat.com - December 6 at 6:58 AMDoing Your Holiday Shopping? These Stocks Might Make Great Gifts (COYA)marketbeat.com - December 4 at 8:12 AMThese biotechs targeting multiple neurodegenerative diseases (COYA)marketbeat.com - December 1 at 8:14 AMCoya Therapeutics, Inc. (COYA) stock price, news, quote & history – Yahoo Financeuk.finance.yahoo.com - November 26 at 8:34 PM Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address “The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months! Click here for all the details now… COYA Media Mentions By Week COYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.260.61▲Average Medical News Sentiment COYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼62▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Corvus Pharmaceuticals News Today Carisma Therapeutics News Today InflaRx News Today Cidara Therapeutics News Today Leap Therapeutics News Today Immunic News Today Regulus Therapeutics News Today Clearside Biomedical News Today Cellectar Biosciences News Today Dyadic International News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.